{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:08:47Z","timestamp":1770491327810,"version":"3.49.0"},"reference-count":83,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.2217\/nmt-2020-0046","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T07:11:28Z","timestamp":1604992288000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Satralizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.1080","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-7521","authenticated-orcid":false,"given":"Ankelien","family":"Duchow","sequence":"first","affiliation":[{"name":"Neurocure Clinical Research Center Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt-Universit\u00e4t zu Berlin & Berlin Institute of Health\rBerlin\r10117\rGermany"},{"name":"Experimental & Clinical Research Center Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt-Universit\u00e4t zu Berlin & Berlin Institute of Health & Max Delbr\u00fcck Center for Molecular Medicine\rBerlin\r13125\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-1643","authenticated-orcid":false,"given":"Judith","family":"Bellmann-Strobl","sequence":"additional","affiliation":[{"name":"Neurocure Clinical Research Center Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt-Universit\u00e4t zu Berlin & Berlin Institute of Health\rBerlin\r10117\rGermany"},{"name":"Experimental & Clinical Research Center Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin Humboldt-Universit\u00e4t zu Berlin & Berlin Institute of Health & Max Delbr\u00fcck Center for Molecular Medicine\rBerlin\r13125\rGermany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00501"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.02.028"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0764"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-14"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8596-7"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa102"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1144-2"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0718-0"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0717-1"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000813"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000062"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00187-3"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903428970"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0961-z"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017385108"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy010"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16625-7"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205351"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2014.938325"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000317"},{"key":"e_1_3_4_29_1","unstructured":"Ringelstein M . Long-term interleukin-6-receptor blockade in neuromyelitis optica spectrum disorder and MOG associated encephalomyelitis (2019). https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2019\/stockholm\/278546\/marius.ringelstein.long-term.interleukin-6-receptor.blockade.in.neuromyelitis.html?f=listing%3D3*browseby%3D8*sortby%3D1*media%3D1"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0533"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30070-3"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101920"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200429010825"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1261-2"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7169-7"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00778"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/2055217318796684"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000580"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000286"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0715-9"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.11.041"},{"key":"e_1_3_4_45_1","unstructured":"European Medicines Agency . Applications for new human medicines under evaluation by the committee for medicinal products for human use (2019). www.ema.europa.eu\/en\/documents\/report\/applications-new-human-medicines-under-evaluation-chmp-october-2019_en.pdf"},{"key":"e_1_3_4_46_1","unstructured":"Chugai Pharmaceutical Co . Chugai receives orphan drug designation for satralizumab in neuromyelitis optica and neuromyelitis optica spectrum disorder from the Ministry of Health Labour and Welfare. (2019) www.chugai-pharm.co.jp\/english\/news\/detail\/20190913140000_646.html"},{"key":"e_1_3_4_47_1","unstructured":"Chugai Pharmaceutical Co . Chugai\u2019s satralizumab receives FDA breakthrough therapy designation for neuromyelitis optica and neuromyelitis optica spectrum disorders. (2018) www.roche.com\/dam\/jcr:0661236f-ed44-4eeb-b5df-b535a532e584\/en\/181219_IR_Chugai_eSatralizumab_BTD.pdf"},{"key":"e_1_3_4_48_1","unstructured":"Roche Hoffmann-La . Product information Enspryng (satralizumab) (2020). www.roche.com\/products\/product-details.htm?productId=6f4b47a2-7ca9-4768-bf1a-6d813702f5b6"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000694"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7991-1"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7925-y"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.216"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511431973"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004087"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517694086"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.03.004"},{"key":"e_1_3_4_59_1","unstructured":"FDA . FDA approves first treatment for neuromyelitis optica spectrum disorder a rare autoimmune disease of the central nervous system (2019). www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central"},{"key":"e_1_3_4_60_1","unstructured":"Alexion Pharmaceuticals . European Commission Approves SOLIRIS\u00ae (eculizumab) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) (2020). https:\/\/ir.alexion.com\/index.php\/news-releases\/news-release-details\/european-commission-approves-solirisr-eculizumab-treatment"},{"key":"e_1_3_4_61_1","unstructured":"Alexion Pharmaceuticals . SOLIRIS\u00ae (eculizumab) receives approval in Japan for the prevention of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) (2019). https:\/\/ir.alexion.com\/news-releases\/news-release-details\/solirisr-eculizumab-receives-approval-japan-prevention-relapse"},{"key":"e_1_3_4_62_1","unstructured":"FDA . FDA approves new therapy for rare disease affecting optic nerve spinal cord (2020). www.fda.gov\/news-events\/press-announcements\/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00888"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1525-1"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25648"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.05.011"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02066"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.08.009"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318465"},{"key":"e_1_3_4_70_1","first-page":"7","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study","author":"Li S","year":"2020","unstructured":"Li S , RenH, XuYet al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol. Neuroimmunol. Neuroinflamm.7 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101430"},{"key":"e_1_3_4_72_1","unstructured":"Shi F . Tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorders (TANGO): a head-to-head comparative study. (2019) https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2019\/stockholm\/279439\/fu-dong.shi.tocilizumab.versus.azathioprine.in.highly.relapsing.neuromyelitis.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D6%2Amedia%3D1%2Ace_id%3D1603%2Aces_id%3D24940%2Amarker%3D624"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315603"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30066-1"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.12.034"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1803828"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1749259"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008394"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12559"},{"key":"e_1_3_4_81_1","unstructured":"Brooks J AtkinsH BoseGet al. Autologous hematopoietic stem cell transplant in patients with severe refractory neuromyelitis optica spectrum disease: the Ottawa experience (2019). https:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2019\/stockholm\/279442\/john.brooks.autologous.hematopoietic.stem.cell.transplant.in.patients.with.html?f=listing%3D3*browseby%3D8*sortby%3D1*media%3D1"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000277"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01169"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000276"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820039116"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2020-0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:46:42Z","timestamp":1716493602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2020-0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.2217\/nmt-2020-0046"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2020-0046","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}